title: A functional polymorphism in the CYR61 (IGFBP10) gene is associated with prostate cancer risk.
abstract: BACKGROUND
  CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and gene expression in Chinese patients.
  
  
  METHODS
  A total of 665 patients diagnosed with PCa and 703 cancer-free controls were genotyped in this hospital-based case-control study, and 26 PCa tissue samples were evaluated for mRNA expression of CYR61 by real-time quantitative reverse-transcription PCR.
  
  
  RESULTS
  Men carrying the G allele of rs3753793 (TG+GG) had significantly lower risk of PCa when compared with the TT genotype (odds ratio (OR) = 0.76, 95% confidence interval (CI) = 0.61-0.95). The association was generally more pronounced among subgroups of PCa patients with advanced stage (OR = 0.70, 95% CI = 0.53-0.94), Gleason score >7 (OR = 0.63, 95% CI = 0.46-0.86) and PSA>20 ng ml(-1) (OR = 0.68, 95% CI = 0.53-0.88). Prostate tumors derived from cases with the GT/GG genotypes had significantly lower levels of CYR61 mRNA when compared with cases with the TT genotypes (P = 0.02).
  
  
  CONCLUSIONS
  Our results indicate that the genetic variation of rs3753793 in the CYR61 promoter may contribute to genetic predisposition to PCa and intra-tumor expression gene expression.
authors.affiliation: State Key Laboratory of Reproductive Medicine, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: L
authors.initials: L
authors.lastname: Tao
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: H
authors.initials: H
authors.lastname: Zhou
authors.forename: C
authors.initials: C
authors.lastname: Qin
authors.forename: P
authors.initials: P
authors.lastname: Li
authors.forename: Q
authors.initials: Q
authors.lastname: Cao
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: X
authors.initials: X
authors.lastname: Ju
authors.forename: C
authors.initials: C
authors.lastname: Zhu
authors.forename: M
authors.initials: M
authors.lastname: Wang
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
authors.forename: P
authors.initials: P
authors.lastname: Shao
authors.forename: C
authors.initials: C
authors.lastname: Yin
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D055515:Cysteine-Rich Protein 61 / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors
chemical_list: C501848:CCN1 protein, human; D055515:Cysteine-Rich Protein 61; D012333:RNA, Messenger